AGFB Fundamental Analysis - AGFA-GEVAERT NV

Fundamental Rating

Overall AGFB gets a fundamental rating of 3 out of 10. We evaluated AGFB against 11 industry peers in the Health Care Technology industry. The financial health of AGFB is average, but there are quite some concerns on its profitability. AGFB has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AGFB has reported negative net income.

AGFB had a positive operating cash flow in the past year.

In the past 5 years AGFB reported 4 times negative net income.

In the past 5 years AGFB always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of AGFB (-4.73%) is worse than 72.73% of its industry peers.

Looking at the Return On Equity, with a value of -21.29%, AGFB is doing worse than 72.73% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-4.73%
ROE	-21.29%
ROIC	N/A

ROA(3y)-8.91%

ROA(5y)0.06%

ROE(3y)-32.3%

ROE(5y)1.63%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of AGFB has declined.

The Gross Margin of AGFB (30.40%) is worse than 81.82% of its industry peers.

In the last couple of years the Gross Margin of AGFB has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for AGFB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	30.4%

OM growth 3Y-1.64%

OM growth 5Y-16.64%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.28%

GM growth 5Y0.88%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AGFB does not have a ROIC to compare to the WACC, probably because it is not profitable.

AGFB has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, AGFB has less shares outstanding

Compared to 1 year ago, AGFB has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 2.25 indicates that AGFB is not a great score, but indicates only limited risk for bankruptcy at the moment.

The Altman-Z score of AGFB (2.25) is comparable to the rest of the industry.

A Debt/Equity ratio of 0.63 indicates that AGFB is somewhat dependend on debt financing.

AGFB has a worse Debt to Equity ratio (0.63) than 63.64% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.63
Debt/FCF	N/A
Altman-Z	2.25

ROIC/WACCN/A

WACC9.05%

2.3 Liquidity

A Current Ratio of 2.08 indicates that AGFB has no problem at all paying its short term obligations.

With a decent Current ratio value of 2.08, AGFB is doing good in the industry, outperforming 63.64% of the companies in the same industry.

AGFB has a Quick Ratio of 1.27. This is a normal value and indicates that AGFB is financially healthy and should not expect problems in meeting its short term obligations.

AGFB's Quick ratio of 1.27 is in line compared to the rest of the industry. AGFB outperforms 45.45% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.08
Quick Ratio	1.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AGFB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -79.84%.

The Revenue has decreased by -0.35% in the past year.

The Revenue for AGFB have been decreasing by -10.44% on average. This is quite bad

EPS 1Y (TTM)-79.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%750%

Revenue 1Y (TTM)-0.35%

Revenue growth 3Y-13.53%

Revenue growth 5Y-10.44%

Sales Q2Q%-1.75%

3.2 Future

AGFB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.19% yearly.

The Revenue is expected to grow by 0.57% on average over the next years.

EPS Next Y109.52%

EPS Next 2Y77.28%

EPS Next 3Y56.83%

EPS Next 5Y32.19%

Revenue Next Year-1.37%

Revenue Next 2Y0.47%

Revenue Next 3Y1.19%

Revenue Next 5Y0.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AGFB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Based on the Price/Forward Earnings ratio of 5.14, the valuation of AGFB can be described as very cheap.

100.00% of the companies in the same industry are more expensive than AGFB, based on the Price/Forward Earnings ratio.

The average S&P500 Price/Forward Earnings ratio is at 36.21. AGFB is valued rather cheaply when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.14

4.2 Price Multiples

AGFB's Enterprise Value to EBITDA ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	13.53

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as AGFB's earnings are expected to grow with 56.83% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y77.28%

EPS Next 3Y56.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AGFB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AGFA-GEVAERT NV

EBR:AGFB (12/2/2025, 10:45:59 AM)

0.629

0 (-0.16%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)11-13 2025-11-13/bmo

Earnings (Next)03-10 2026-03-10/amc

Inst Owners51.79%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap97.38M

Revenue(TTM)1.13B

Net Income(TTM)-66.00M

Analysts75.56

Price Target1.02 (62.16%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-16.67%

PT rev (3m)-14.29%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-66.67%

Revenue NQ rev (1m)-2.78%

Revenue NQ rev (3m)-2.78%

Revenue NY rev (1m)-0.09%

Revenue NY rev (3m)-2.46%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.14
P/S	0.09
P/FCF	N/A
P/OCF	2.78
P/B	0.31
P/tB	1.28
EV/EBITDA	13.53

EPS(TTM)-0.43

EYN/A

EPS(NY)0.12

Fwd EY19.46%

FCF(TTM)-0.03

FCFYN/A

OCF(TTM)0.23

OCFY35.94%

SpS7.27

BVpS2

TBVpS0.49

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.73%
ROE	-21.29%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	30.4%
FCFM	N/A

ROA(3y)-8.91%

ROA(5y)0.06%

ROE(3y)-32.3%

ROE(5y)1.63%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-1.64%

OM growth 5Y-16.64%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.28%

GM growth 5Y0.88%

F-Score3

Asset Turnover0.81

Health

		Industry Rank	Sector Rank
Debt/Equity	0.63
Debt/FCF	N/A
Debt/EBITDA	12.13
Cap/Depr	105.26%
Cap/Sales	3.56%
Interest Coverage	N/A
Cash Conversion	218.75%
Profit Quality	N/A
Current Ratio	2.08
Quick Ratio	1.27
Altman-Z	2.25

F-Score3

WACC9.05%

ROIC/WACCN/A

Cap/Depr(3y)78.36%

Cap/Depr(5y)64.97%

Cap/Sales(3y)3.26%

Cap/Sales(5y)2.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-79.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%750%

EPS Next Y109.52%

EPS Next 2Y77.28%

EPS Next 3Y56.83%

EPS Next 5Y32.19%

Revenue 1Y (TTM)-0.35%

Revenue growth 3Y-13.53%

Revenue growth 5Y-10.44%

Sales Q2Q%-1.75%

Revenue Next Year-1.37%

Revenue Next 2Y0.47%

Revenue Next 3Y1.19%

Revenue Next 5Y0.57%

EBIT growth 1Y-650%

EBIT growth 3Y-14.94%

EBIT growth 5Y-25.35%

EBIT Next Year258.64%

EBIT Next 3Y64.43%

EBIT Next 5Y43.36%

FCF growth 1Y95.69%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y142.68%

OCF growth 3YN/A

OCF growth 5YN/A

AGFA-GEVAERT NV / AGFB.BR FAQ

What is the fundamental rating for AGFB stock?

ChartMill assigns a fundamental rating of 3 / 10 to AGFB.BR.

What is the valuation status of AGFA-GEVAERT NV (AGFB.BR) stock?

ChartMill assigns a valuation rating of 5 / 10 to AGFA-GEVAERT NV (AGFB.BR). This can be considered as Fairly Valued.

How profitable is AGFA-GEVAERT NV (AGFB.BR) stock?

AGFA-GEVAERT NV (AGFB.BR) has a profitability rating of 1 / 10.

What is the financial health of AGFA-GEVAERT NV (AGFB.BR) stock?

The financial health rating of AGFA-GEVAERT NV (AGFB.BR) is 4 / 10.

AGFA-GEVAERT NV (AGFB.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AGFA-GEVAERT NV / AGFB.BR FAQ

What is the fundamental rating for AGFB stock?

What is the valuation status of AGFA-GEVAERT NV (AGFB.BR) stock?

How profitable is AGFA-GEVAERT NV (AGFB.BR) stock?

What is the financial health of AGFA-GEVAERT NV (AGFB.BR) stock?